Carmila CARM

PAR: CARM | ISIN: FR0010828137 11/10/2024

18,32 EUR (+1,78%)

(+1,78%) 11/10/2024

Grafiek Carmila

Grafiek Carmila

1 dag1d 1,78%
1 week1w 2,46%
1 maand1m 3,62%
3 maanden3m 10,36%
6 maanden6m 14,79%
1 jaar1j 36,92%
5 jaar5j 14,93%

Carmila in het nieuws

Toon enkel gratis nieuws

8 augustus 2024 · Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

9 mei 2024 · Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

8 mei 2024 · Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 · Persbericht

9 november 2023 · Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

14 juni 2023 · Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources · Persbericht

5 juni 2023 · Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023 · Persbericht

11 mei 2023 · Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights · Persbericht

14 april 2023 · Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting · Persbericht

4 april 2023 · Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights · Persbericht

Profiel Carmila

CEO: Alexandre de Palmas

Werknemers: 77

Aandelen Carmila

Beurswaarde: 2,40 miljard EUR

Effecten: 142,44 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe